ES2340473T3 - Venenos de topoisomerasas solubilizadas. - Google Patents

Venenos de topoisomerasas solubilizadas. Download PDF

Info

Publication number
ES2340473T3
ES2340473T3 ES02801198T ES02801198T ES2340473T3 ES 2340473 T3 ES2340473 T3 ES 2340473T3 ES 02801198 T ES02801198 T ES 02801198T ES 02801198 T ES02801198 T ES 02801198T ES 2340473 T3 ES2340473 T3 ES 2340473T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
substituted
formula
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02801198T
Other languages
English (en)
Spanish (es)
Inventor
Edmond J. Lavoie
Alexander L. Ruchelman
Leroy F. Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Application granted granted Critical
Publication of ES2340473T3 publication Critical patent/ES2340473T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Toys (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Confectionery (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES02801198T 2001-11-14 2002-11-14 Venenos de topoisomerasas solubilizadas. Expired - Lifetime ES2340473T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33273401P 2001-11-14 2001-11-14
US332734P 2001-11-14

Publications (1)

Publication Number Publication Date
ES2340473T3 true ES2340473T3 (es) 2010-06-04

Family

ID=23299632

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02801198T Expired - Lifetime ES2340473T3 (es) 2001-11-14 2002-11-14 Venenos de topoisomerasas solubilizadas.

Country Status (15)

Country Link
US (4) US7049315B2 (US07049315-20060523-C00023.png)
EP (3) EP2286812A1 (US07049315-20060523-C00023.png)
JP (3) JP4628675B2 (US07049315-20060523-C00023.png)
KR (1) KR20050044491A (US07049315-20060523-C00023.png)
AT (1) ATE456952T1 (US07049315-20060523-C00023.png)
AU (1) AU2002363658B2 (US07049315-20060523-C00023.png)
CA (1) CA2467774C (US07049315-20060523-C00023.png)
CY (1) CY1110631T1 (US07049315-20060523-C00023.png)
DE (1) DE60235287D1 (US07049315-20060523-C00023.png)
DK (1) DK1465625T3 (US07049315-20060523-C00023.png)
ES (1) ES2340473T3 (US07049315-20060523-C00023.png)
MX (1) MXPA04004606A (US07049315-20060523-C00023.png)
PT (1) PT1465625E (US07049315-20060523-C00023.png)
SI (1) SI1465625T1 (US07049315-20060523-C00023.png)
WO (1) WO2003041660A2 (US07049315-20060523-C00023.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004606A (es) 2001-11-14 2004-09-10 Univ Rutgers Venenos de topoisomerasa solubilizados.
WO2003051289A2 (en) 2001-11-14 2003-06-26 Rutgers, The State University Solubilized topoisomerase poison agents
ES2311639T3 (es) 2001-11-14 2009-02-16 Rutgers, The State University Agentes citotoxicos.
ATE390923T1 (de) 2001-11-14 2008-04-15 Univ Rutgers Topoisomerase-giftmittel
AU2003265406A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2003265405A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted heterocycles as topoisomerase i targeting agents
EP1562593B1 (en) * 2002-11-12 2014-07-16 Rutgers, The State University of New Jersey Topoisomerase-targeting agents
EP1778228A4 (en) * 2004-07-09 2010-08-11 Medisyn Technologies Inc THERAPEUTIC CONNECTION AND TREATMENTS
KR20090040265A (ko) * 2006-05-24 2009-04-23 닥터 레디스 레보러터리즈 리미티드 5(ｓ)-(2'-히드록시에톡시)-20(ｓ)-캄프토테신의 결정질 형태
CN102256966B (zh) 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
TW201038578A (en) * 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
ES2401563T3 (es) 2009-03-06 2013-04-22 Rutgers, The State University Of New Jersey Derivados de metilendioxibenzo [I]fenantridina usados para tratar el cáncer
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2010127360A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2012015901A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating gastric and pancreatic malignancies
WO2012015875A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating hematological malignancies
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
CN109219610A (zh) 2016-04-04 2019-01-15 新泽西州立拉特格斯大学 拓扑异构酶毒物
CN111925370B (zh) * 2020-09-01 2023-07-21 湖北科苑生物药业有限公司 一种吡嗪并吡唑并萘啶类化合物及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) 1961-04-25 Acridine derivatives
US2985681A (en) * 1953-08-28 1961-05-23 Knoll Ag Phenylacetic acid and aminoalkyl esters thereof
US2985661A (en) 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420044A (de) 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Azol-Derivaten als optische Aufheller für textile organische Materialien
US3267107A (en) 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (US07049315-20060523-C00023.png) 1972-08-25 1974-04-22
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4980344A (en) 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
US5153178A (en) 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
US4749708A (en) 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd １３−プロピルベルベリンの塩
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
DE4116593C1 (US07049315-20060523-C00023.png) * 1991-05-22 1993-01-07 Fa. Hermann Heye, 3063 Obernkirchen, De
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
EP0721942B1 (en) 1993-09-28 2002-06-05 Kyowa Hakko Kogyo Co., Ltd. Tetracyclic compound
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
AU713317B2 (en) 1995-05-17 1999-11-25 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
CN1067070C (zh) 1996-02-12 2001-06-13 新泽西州州立大学(拉特格斯) 用作拓扑异构酶抑制剂的甲氧檗因类似物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
US5981541A (en) 1996-09-23 1999-11-09 Rutgers, The State University Of New Jersey Substituted heterocycles as anti-tumor agents
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
JP4580556B2 (ja) 1998-10-14 2010-11-17 パーデュー リサーチ ファウンデイション 抗腫瘍薬である新規インデノイソキノリン類
EP1228045A2 (en) 1999-10-29 2002-08-07 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
JP2005515180A (ja) 2001-11-13 2005-05-26 ザ プロクター アンド ギャンブル カンパニー 阻害物質で安定化させた酵素を含有する局所適用組成物
MXPA04004606A (es) 2001-11-14 2004-09-10 Univ Rutgers Venenos de topoisomerasa solubilizados.
ES2311639T3 (es) * 2001-11-14 2009-02-16 Rutgers, The State University Agentes citotoxicos.
ATE390923T1 (de) 2001-11-14 2008-04-15 Univ Rutgers Topoisomerase-giftmittel
WO2003051289A2 (en) 2001-11-14 2003-06-26 Rutgers, The State University Solubilized topoisomerase poison agents
US7493607B2 (en) * 2002-07-09 2009-02-17 Bluerisc Inc. Statically speculative compilation and execution
AU2003265405A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted heterocycles as topoisomerase i targeting agents
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2003265406A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
EP1562593B1 (en) * 2002-11-12 2014-07-16 Rutgers, The State University of New Jersey Topoisomerase-targeting agents

Also Published As

Publication number Publication date
JP2005511617A (ja) 2005-04-28
EP2196205A1 (en) 2010-06-16
KR20050044491A (ko) 2005-05-12
US20090239871A1 (en) 2009-09-24
CA2467774C (en) 2011-09-20
US7049315B2 (en) 2006-05-23
ATE456952T1 (de) 2010-02-15
EP1465625B1 (en) 2010-02-03
WO2003041660A2 (en) 2003-05-22
JP2010184942A (ja) 2010-08-26
JP5337104B2 (ja) 2013-11-06
US20060052381A1 (en) 2006-03-09
DE60235287D1 (de) 2010-03-25
WO2003041660A3 (en) 2003-10-16
CY1110631T1 (el) 2015-04-29
US7517883B2 (en) 2009-04-14
AU2002363658B2 (en) 2008-09-11
EP1465625A2 (en) 2004-10-13
EP2286812A1 (en) 2011-02-23
US20050009824A1 (en) 2005-01-13
US7781587B2 (en) 2010-08-24
JP2013166801A (ja) 2013-08-29
PT1465625E (pt) 2010-03-09
CA2467774A1 (en) 2003-05-22
DK1465625T3 (da) 2010-05-31
US20110136812A1 (en) 2011-06-09
EP1465625A4 (en) 2005-06-08
MXPA04004606A (es) 2004-09-10
SI1465625T1 (sl) 2010-06-30
JP4628675B2 (ja) 2011-02-09
US8389721B2 (en) 2013-03-05

Similar Documents

Publication Publication Date Title
ES2340473T3 (es) Venenos de topoisomerasas solubilizadas.
ES2311639T3 (es) Agentes citotoxicos.
AU2002363658A1 (en) Solubilized topoisomerase poisons
US20060058306A1 (en) Solubilized topoisomerase poison agents
JP4774212B2 (ja) トポイソメラーゼ−ターゲッティング剤
AU2010208042A1 (en) Methods to treat cancer
WO2012015875A1 (en) Methods for treating hematological malignancies